REFERENCES
- Munoz MA, Arrivi A, Guaraz R et al. VP-16 ifosfamide, and cisplatin (VIP) as treatment of small cell lung cancer: A preliminary report. Presented at 4th European Conference on Clinical Oncology and Cancer Nursing, Madrid, Spain, Federation of European Cancer Societies. 1987; 26.
- Miller JC, Loeher PJ, Songer J, et al. VP-16, ifosfamide and cisplatin (VIP) in extensive small cell lung cancer: A Hoosier Oncology Group Study. Proc Am Soc Clin Oncol 1990; 9: 248 (Abstr).
- Carney DM, Grogan L. Phase II study of VP-16, ifos-famide and cisplatin (VIP) in small cell and non-small cell lung cancer. Proc Am Soc Clin Oncol 1990; 9: 244 (Abstr).
- Evans WK, Stewart D, Logan D, et al. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer. Semin Oncol 1992; 19: 51–57.
- Crawford J, Ozer H, Stoller R, et al. Reduction by gran-ulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung can-cer. N Engl J Med 1991; 325: 164–170.
- Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319–324.
- Ihde DC, Hansen HH. Staging procedures and prog-nostic factors in small cell carcinoma of the lung. In Greco FA, Oldman RK, Bunn PA ( eds): Small cell lung cancer. New York, NY, Grune and Stratton 1981: 261-283.
- World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No: 48. Geneva, Switzerland, World Health Organization 1979.
- BMDP Statistical Software Manual. University of California Press. Los Angeles 1992; 2: 795–824.
- Ihde DC, Pass HI, Glatstein EJ. Small cell lung cancer, In De Vita LT, Hellman S, Rosenberg SA ( eds): Cancer Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1993: 723-758.
- Drings P. Ifosfamide in the treatment of bronchial car-cinoma. Contrib Oncol 1987; 26: 294–318.
- Einhorn LH, Loehrer PJ. Hoosier Oncology Group Studies in extensive and recurrent small cell lung cancer. Semin Oncol 1995; 22: 28–31.
- Loehrer PJ, Rynard S, Ansari R, et al. Etoposide, ifos-famide and cisplatin in extensive small cell lung cancer. Cancer 1992; 69: 669–673.
- Loehrer PJ, Williams SD, Nichols CR, Einhorn LH. Clinical trials with ifosfamide: The Indiana University Experience. Semin Oncol 1992; 19: 35–39.
- Ettinger DS. Overview of ifosfamide in small cell lung cancer. Semin Oncol 1992; 19: 59–67.
- Thatcher N, Lind M, Stout R, et al. Carboplatin, ifos-famide and etoposide with mid-course vincristine and tho-racic radiotherapy for “limited” stage small cell carcinoma of the bronchus. Br J Cancer 1989; 8: 98–101.
- Ettinger DS. The place of ifosfamide in chemotherapy of small cell lung cancer: The Eastern Cooperative Oncology Group experience and a selected literature update. Semin Oncol 1995; 22: 23–27.
- Petros \VP, Peters \VP. Hematopoietic colony-stimulat-ing factors and dose intensity. Semin Oncol 1993; 20: 94–99.
- Saijo N, Egucki K, Etou H, et al. The role of granulo-cyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer. Semin Oncol 1994; 21: 54–58.
- Rosell R, Gomez-Codina J, Anton A, et al. Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate. Semin Oncol 1994; 21: 48–53.
- Thatcher N, Anderson H, Bleehen NM, et al. The feasi-bility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etopo-side (ACE) in the treatment of small cell lung cancer. Eur J Cancer 1995; 31A: 152–156.
- Bronchud MH, Scarffe JH, Thatcher N et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56: 809–813.
- Hansen HH, Kristjansen PEG, Andersen M. The role of hematopoietic growth factors. In Denis L ( ed): Small cell lung cancer. Consultant series No: 3, Gardiner-Caldwell Communications 1991: 21-28.